Headlines about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.3201512239062 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- 3 Growth Stocks for Successful Investors (finance.yahoo.com)
- Reader Inquiry: What’s The Outlook For Atara Biotherapeutics After The Recent Secondary? (seekingalpha.com)
- Atara Biotherapeutics, Inc. (ATRA) stock is 80.94% above to 200- SMA (thestocksnews.com)
- Global Growth/Differentiation Factor 8 Market Analysis 2018 Acceleron Pharma, Atara Biotherapeutics, Bristol-Myers … (newspharmaceuticals.com)
- Technical Indicators under Consideration – Atara Biotherapeutics Inc (NASDAQ: ATRA) (alphabetastock.com)
ATRA opened at $39.50 on Friday. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $49.90. The firm has a market cap of $1,529.74, a price-to-earnings ratio of -9.88 and a beta of 2.55.
A number of research analysts recently issued reports on the stock. JPMorgan Chase assumed coverage on shares of Atara Biotherapeutics in a research report on Tuesday, April 10th. They set an “overweight” rating and a $56.00 target price on the stock. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, April 6th. BidaskClub downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. ValuEngine upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Guggenheim assumed coverage on shares of Atara Biotherapeutics in a research report on Thursday, March 15th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $37.50.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 10,000 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $33.07, for a total transaction of $330,700.00. Following the transaction, the chief executive officer now owns 348,978 shares in the company, valued at $11,540,702.46. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Heather D. Turner sold 12,214 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $38.01, for a total transaction of $464,254.14. Following the transaction, the executive vice president now owns 77,112 shares in the company, valued at approximately $2,931,027.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 244,824 shares of company stock worth $9,854,461. Corporate insiders own 16.20% of the company’s stock.
WARNING: “Atara Biotherapeutics (ATRA) Earning Somewhat Positive Press Coverage, Accern Reports” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3378684/atara-biotherapeutics-atra-earning-somewhat-positive-press-coverage-accern-reports.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.